DLEC1 Polyclonal Antibody,Abbkine_specification/price/image

Product Detail
Company Profile

The cytogenetic location of DLEC1（deleted in lung and esophageal cancer 1) is 3p21.3, and it is located in a region that is commonly deleted in a variety of malignancies. Down-regulation of DLEC1 has been observed in several human cancers including lung, esophageal, renal tumors, and head and neck squamous cell carcinoma. In some cases, reduced expression of DLEC1 in tumor cells is a result of aberrant promoter methylation. Several alternatively spliced transcripts have been observed that contain disrupted coding regions and likely encode nonfunctional proteins.

DLEC1 Polyclonal Antibody detects endogenous levels of DLEC1 protein.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: IHC-p: 1:100-1:300, IF: 1:200-1:1000, ELISA: 1:10000. Not yet tested in other applications.

DLEC1 Polyclonal Antibody product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Find more details at http://www.abbkine.com/product/dlec1-polyclonal-antibody-abp57140.

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.